Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Trends in Costs of Thyroid Disease Treatment in Denmark during 1995-2015

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Risk of Thyroid Cancer in 1,504 Patients Referred for Thyroid Surgery with Assumed Benign Histology

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. High Level of Agreement between Electronic and Paper Mode of Administration of a Thyroid-Specific Patient-Reported Outcome, ThyPRO

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Treating Hypothyroidism with Thyroxine/Triiodothyronine Combination Therapy in Denmark: Following Guidelines or Following Trends?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Evaluation of Serum Insulin-like Factor 3 Quantification by LC-MS/MS as a Biomarker of Leydig Cell Function

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gain-of-function mutation in the voltage-gated potassium channel gene KCNQ1 and glucose-stimulated hypoinsulinemia - case report

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sex-specific estrogen levels and reference intervals from infancy to late adulthood determined by LC-MS/MS

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Line Tang Møllehave
  • Allan Linneberg
  • Tea Skaaby
  • Nils Knudsen
  • Lars Ehlers
  • Torben Jørgensen
  • Betina Heinsbæk Thuesen
View graph of relations

Background: Iodine fortification (IF) may contribute to changes in costs of thyroid disease treatment through changes in disease patterns. From a health economic perspective, assessment of the development in costs of thyroid disease treatment in the population is pertinent.

Objectives: To assess the trends in annual medicine and hospital costs of thyroid disease treatment during 1995-2015 in Denmark, i.e., before and after the introduction of mandatory IF in 2000.

Methods: Information on treatments for thyroid disease (antithyroid medication, thyroid hormone therapy, thyroid surgery, and radioiodine treatment) was obtained from nationwide registers. Costs were valued at 2015 prices using sales prices for medicines and the Danish Diagnosis-Related Group (DRG) and Danish Ambulatory Grouping System (DAGS) tariffs of surgeries/radioiodine treatments. Results were adjusted for changes in population size and age and sex distribution.

Results: The total direct medicine and hospital costs of thyroid disease treatment increased from EUR ∼190,000 per 100,000 persons in 1995 to EUR ∼270,000 per 100,000 persons in 2015. This was mainly due to linearly increased costs of thyroid hormone therapy and increased costs of thyroid surgery since 2008. Costs of antithyroid medication increased slightly and transiently after IF, while costs of radioiodine treatment remained constant. Costs of thyroid hormone therapy and thyroid surgery did not follow the development in the prevalence of hypothyroidism and structural thyroid diseases observed in concurrent studies.

Conclusion: The costs of total direct medicine and hospital costs for thyroid disease treatment in Denmark increased from 1995 to 2015. This is possibly due to several factors, e.g., changes in treatment practices, and the direct effect of IF alone remains to be estimated.

Original languageEnglish
JournalEuropean Thyroid Journal
Volume7
Issue number2
Pages (from-to)75-83
Number of pages9
ISSN2235-0640
DOIs
Publication statusPublished - Mar 2018

    Research areas

  • Journal Article

ID: 53659091